Lawton C A, Cohen E P, Murray K J, Derus S W, Casper J T, Drobyski W R, Horowitz M M, Moulder J E
Radiation Oncology, Medical College of Wisconsin, Milwaukee 53226, USA.
Bone Marrow Transplant. 1997 Dec;20(12):1069-74. doi: 10.1038/sj.bmt.1701022.
The purpose of this study was to evaluate the effect of partial renal shielding used in conjunction with total body irradiation (TBI) on the incidence of bone marrow transplantation nephropathy (BMT Np) seen as a late sequelae after transplantation. Of 402 patients who have undergone bone marrow transplantation (BMT) at the Medical College of Wisconsin (MCW) 157 were greater than 18 years of age, received 14 Gy TBI and survived at least 100 days post-transplant. The incidence of BMT nephropathy was evaluated in these patients by dose to the kidneys. In the 72 patients who received 14 Gy TBI with no renal shielding, the actuarial risk of developing BMT Np at 2 1/2 years (30 months) post-BMT was 29 +/- 7%. Sixty-eight patients received 14 Gy TBI with partial renal shielding of 15% (renal dose = 11.9 Gy), the actuarial risk of developing BMT Np was 14 +/- 5% at 2 1/2 years. Seventeen patients received 14 Gy TBI with renal shielding of 30% (renal dose = 9.8 Gy); none of this group have developed BMT Np despite a median follow-up of over 2 1/2 years (985 days). The trend of decreasing BMT Np with increasing shielding is statistically significant (P = 0.012). Prognostic factors such as age, type of transplant and good-risk vs poor-risk disease status were evaluated and were similar in each cohort of patients described above. We conclude that given the statistically significant benefit seen here in the reduced incidence of BMT Np by the use of selective renal shielding, this should be seriously considered for all patients who receive TBI, but especially for patients whose renal doses exceed 10 Gy.
本研究的目的是评估在全身照射(TBI)中联合使用部分肾脏屏蔽对移植后晚期后遗症骨髓移植肾病(BMT Np)发生率的影响。在威斯康星医学院(MCW)接受骨髓移植(BMT)的402例患者中,157例年龄大于18岁,接受了14 Gy的TBI,且移植后存活至少100天。通过肾脏剂量评估这些患者的BMT肾病发生率。在72例接受14 Gy TBI且未进行肾脏屏蔽的患者中,BMT后2.5年(30个月)发生BMT Np的精算风险为29±7%。68例患者接受了15%的部分肾脏屏蔽(肾脏剂量=11.9 Gy)的14 Gy TBI,2.5年时发生BMT Np的精算风险为14±5%。17例患者接受了30%的肾脏屏蔽(肾脏剂量=9.8 Gy)的14 Gy TBI;尽管中位随访超过2.5年(985天),该组患者均未发生BMT Np。随着屏蔽增加BMT Np发生率降低的趋势具有统计学意义(P = 0.012)。对年龄、移植类型以及良好风险与不良风险疾病状态等预后因素进行了评估,上述每组患者的这些因素相似。我们得出结论,鉴于此处观察到使用选择性肾脏屏蔽可使BMT Np发生率显著降低,对于所有接受TBI的患者,尤其是肾脏剂量超过10 Gy的患者,应认真考虑这一方法。